MetaCap

MoonLake Immunotherapeutics Balance Sheet

NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.82+0.24 (+2.27%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

MoonLake Immunotherapeutics financial position

At the end of fiscal 2025, MoonLake Immunotherapeutics reported total assets of $424.4 million, down 11.2% from a year earlier against total liabilities of $120.0 million. Shareholders' equity stood at $304.5 million, or 71.7% of assets. The company held $334.5 million in cash and equivalents against $74.1 million of debt, a net cash position of $260.4 million.

The current ratio (current assets divided by current liabilities) was 9.27, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.24.

Summary generated from market data by MetaCap's automated system. Methodology

MoonLake Immunotherapeutics balance sheet (annual)

MoonLake Immunotherapeutics annual balance sheet
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31
Cash & Equivalents334.52M180.43M451.17M39.51M8.04M
Short-Term Investments59.45M267.60M59.84M32.61M0
Total Current Assets421.69M474.29M514.17M76.51M9.64M
Property, Plant & Equipment577.00K722.00K320.87K49.39K45.74K
Total Assets424.43M477.93M526.54M76.84M9.68M
Short-Term Debt———015.00M
Total Current Liabilities45.48M22.46M9.97M7.67M21.09M
Long-Term Debt74.10M0———
Total Liabilities119.95M24.54M13.05M8.08M21.33M
Shareholders' Equity304.48M446.82M495.68M48.90M-11.65M
Retained Earnings-462.91M-235.59M-116.66M-80.65M-53.64M
Total Debt74.10M0—015.00M
Net Cash (Debt)319.87M448.03M511.01M72.11M-6.96M

This table shows 5 annual periods of MoonLake Immunotherapeutics's balance sheet, from FY 2025 back to FY 2021, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow MLTX's reporting calendar. What is a balance sheet?

More financial data